An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 forTreatment of Opioid-Induced Constipation in Subjects With Nonmalignant PainEstudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en suj

Primary: The primary objective of the study is to evaluate the long-term safety and tolerability of the subcutaneous formulation of MOA-728 in subjects with opioid-induced constipation who have nonmalignant pain.
Primary endpoints: Safety and tolerability will be evaluated by collection of adverse events, laboratory assessments, physical examinations, vital signs measurements, electrocardiograms, Pain Intensity Scale, and the opioid withdrawal scales.